Eli Lilly and Company Licenses U.S. Rights for Tadalafil PAH Indication to United Therapeutics Corporation | FierceBiotech
`
`Page 1 of 4
`
`
`
`
`
`Register for Fierce JPM Week 2021
`Join us Jan 11-13 for a three-day virtual event exploring the latest issues, from COVID-19 to the post-pandemic future
`
`Biotech
`Eli Lilly and Company Licenses U.S. Rights for Tadalafil PAH Indication to United Therapeutics
`Corporation
`
`by Calisha Myers | Nov 17, 2008 11:43am
`
`Eli Lilly and Company Licenses U.S. Rights for Tadalafil PAH Indication to United Therapeutics Corporation;
`Lilly Takes $150 Million Equity Stake in United Therapeutics
`
`INDIANAPOLIS and SILVER SPRING, Md., Nov. 17 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY)
`and United Therapeutics Corporation (Nasdaq: UTHR) today announced that the two companies have entered
`into a license and a supply agreement related to the U.S. commercialization rights for the pulmonary arterial
`hypertension (PAH) indication of Lilly's molecule, tadalafil. The PAH indication is currently under regulatory
`review in the United States, Canada, Mexico, Japan and the European Union.
`
`Under the terms of the agreements, United Therapeutics will make an upfront payment of $150 million to Lilly
`for the exclusive rights to commercialize tadalafil for PAH in the United States, as well as for a product
`manufacturing and supply arrangement. Lilly will manufacture and supply tadalafil to United Therapeutics and
`will retain authority globally for all regulatory, development, intellectual property and manufacturing aspects of
`the tadalafil molecule for all potential indications. Lilly will also retain commercialization rights to tadalafil for
`PAH outside of the U.S. In addition, Lilly will purchase $150 million of common stock from United Therapeutics.
`The transaction is subject to clearance of the stock purchase under the Hart-Scott-Rodino Antitrust
`Improvements Act and other customary closing conditions.
`
`"United Therapeutics brings substantial expertise and passion to the treatment of patients with PAH and will be
`an excellent partner for this product," commented Dr. Gwen G. Krivi, Ph.D., vice president of Lilly Research Labs
`and global brand development platform leader for Lilly. "Their experience in this field will greatly enhance the
`ability to provide tadalafil for PAH, if approved, as a new therapeutic option for this very serious disease. We are
`also pleased to make a financial investment in a promising and profitable biotechnology company. The
`collaboration with United Therapeutics adds to the success of Lilly's networking strategy."
`
`"The addition of tadalafil for PAH expands our portfolio and strengthens United Therapeutics' position in the
`area of cardiovascular disease," said Martine Rothblatt, Ph.D, chairman and chief executive officer of United
`Therapeutics. "Building upon the success of Remodulin, we are committed to addressing the unmet medical
`needs of patients. We also welcome the support and confidence expressed by Lilly through their financial
`investment in our company."
`
`About Pulmonary Arterial Hypertension
`
`https://www.fiercebiotech.com/biotech/eli-lilly-and-company-licenses-u-s-rights-for-tadalafil-pah-indication-to-united
`
`Liquidia's Exhibit 1075
`Page 1
`
`

`

`Eli Lilly and Company Licenses U.S. Rights for Tadalafil PAH Indication to United Therapeutics Corporation | FierceBiotech
`
`Page 2 of 4
`
`Pulmonary arterial hypertension (PAH) is a rare blood vessel disorder of the lung in which the pressure in the
`pulmonary artery (the blood vessel that leads from the heart to the lungs) rises above normal levels. It is a
`severe, chronic and life threatening disease.
`
`About United Therapeutics
`
`United Therapeutics is a biotechnology company focused on the development and commercialization of unique
`products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and
`infectious diseases and cancer. [uthr-g]
`
`About Lilly
`
`Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-
`class pharmaceutical products by applying the latest research from its own worldwide laboratories and from
`collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers
`-- through medicines and information -- for some of the world's most urgent medical needs. Additional
`information about Lilly is available at www.lilly.com. C-LLY
`
`This news release contains forward-looking statements. These statements are subject to known and unknown
`risks and uncertainties that may cause actual future experience and results to differ materially from the
`statements made. Factors that might cause such a difference include, among others, the completion of clinical
`trials, the FDA review processes and other governmental regulation, United Therapeutics' ability to
`successfully develop and commercialize drug candidates, competition from other pharmaceutical companies,
`the ability to effectively market products, and other factors described in Lilly's and United Therapeutics' most
`recent filings with the Securities and Exchange Commission. Neither Lilly nor United Therapeutics undertakes
`any duty to update forward looking statements.
`
`SOURCE Eli Lilly and Company
`
`VIRTUAL CLINICAL TRIALS SUMMIT
`Virtual Clinical Trials Summit: The Premier Educational Event
`Focused on Decentralized Clinical Trials
`In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into
`the many ways companies can improve patient engagement and trial behavior to enhance retention with
`a focus on emerging technology and harmonized data access across the clinical trial system.
`
`REGISTER NOW
`
`https://www.fiercebiotech.com/biotech/eli-lilly-and-company-licenses-u-s-rights-for-tadalafil-pah-indication-to-united
`
`Liquidia's Exhibit 1075
`Page 2
`
`

`

`Eli Lilly and Company Licenses U.S. Rights for Tadalafil PAH Indication to United Therapeutics Corporation | FierceBiotech
`
`Page 3 of 4
`
`GET THE NEWSLETTER
`Subscribe to FierceBiotech to get
`industry news and updates delivered to
`your inbox.
`
`Email
`
`SIGN UP
`
`I acknowledge that I may receive emails
`from FierceBiotech and on behalf of
`their trusted partners.
`
`About the Author
`
`alisha Myers
`
`C
`
`GENERAL
`
`Home
`
`Privacy
`
`Terms Of Use
`
`RSS
`
`CONTACT
`
`Advertise
`
`About Us
`
`NEWSLETTERS
`
`CONNECT
`
`Subscribe
`
`Manage Subscriptions
`
`https://www.fiercebiotech.com/biotech/eli-lilly-and-company-licenses-u-s-rights-for-tadalafil-pah-indication-to-united
`
`Liquidia's Exhibit 1075
`Page 3
`
`

`

`Eli Lilly and Company Licenses U.S. Rights for Tadalafil PAH Indication to United Therapeutics Corporation | FierceBiotech
`
`Page 4 of 4
`
`© 2021 Questex LLC. All rights reserved. 3 Speen Street, Suite 300, Framingham, MA 01701
`
`Reproduction in whole or part is prohibited.
`
`https://www.fiercebiotech.com/biotech/eli-lilly-and-company-licenses-u-s-rights-for-tadalafil-pah-indication-to-united
`
`Liquidia's Exhibit 1075
`Page 4
`
`